Preliminary Evidence of Anti-tumor and Anti-Resorptive Activities at Tolerable Dose
MOSCOW, Russia I June 1, 2017 I Osteros Biomedica announces the completion of Phase 1 clinical trial of its drug МВС-11 intended to treat patients with bone metastases and their associated clinical consequences. The results will be presented to the ASCO conference that will be held in Chicago on June, 2-7 2017.
The trial assessed safety and tolerability of MВС-11 when repeatedly used in various doses and determined a suitable range of doses for subsequent disease-directed studies. It also obtained preliminary efficacy data using positron emission tomography and various other markers of potential drug effect.
MBC-11 is a first-in-class therapeutic conjugate of the bone targeting bisphosphonate etidronate covalently linked to the antimetabolite cytosine arabinoside (Ara-C). A first-in-human phase 1, pharmacokinetic and pharmacodynamic study of MBC-11 has been completed in advanced cancer patients with bone metastases and phase 2/proof-of-concept studies are being planned.
Alexander Karpeisky, Chief Scientific Advisor of Osteros Biomedica commented, “We are excited to see very promising results in this Phase 1 trial in patients with cancer-induced bone disease. Favorable safety profile together with MBC-11-dependent significant reduction in metabolic activity of bone lesions validate its further clinical development.”
The poster will be presented in the sessions listed below.
Abstract Number: 2589
Abstract Title: Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases.
Poster Board: 81
Presentation Date and Time: 6/5/2017, 8:00 AM-11:30 AM
Location: McCormick Place: Hall A
About Osteros Biomedica
Osteros Biomedica is Maxwell Biotech Venture Fund’s Portfolio Company. The Company’s main goal is to develop and commercialize innovative the drugs for the treatment of cancer induced bone disease. The company has the global rights for its first product MBC-11 which is being developed in collaboration with an American biotech company MBC Pharma.
About Maxwell Biotech Venture Fund
Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development.
SOURCE: Osteros Biomedica
Post Views: 164
Preliminary Evidence of Anti-tumor and Anti-Resorptive Activities at Tolerable Dose
MOSCOW, Russia I June 1, 2017 I Osteros Biomedica announces the completion of Phase 1 clinical trial of its drug МВС-11 intended to treat patients with bone metastases and their associated clinical consequences. The results will be presented to the ASCO conference that will be held in Chicago on June, 2-7 2017.
The trial assessed safety and tolerability of MВС-11 when repeatedly used in various doses and determined a suitable range of doses for subsequent disease-directed studies. It also obtained preliminary efficacy data using positron emission tomography and various other markers of potential drug effect.
MBC-11 is a first-in-class therapeutic conjugate of the bone targeting bisphosphonate etidronate covalently linked to the antimetabolite cytosine arabinoside (Ara-C). A first-in-human phase 1, pharmacokinetic and pharmacodynamic study of MBC-11 has been completed in advanced cancer patients with bone metastases and phase 2/proof-of-concept studies are being planned.
Alexander Karpeisky, Chief Scientific Advisor of Osteros Biomedica commented, “We are excited to see very promising results in this Phase 1 trial in patients with cancer-induced bone disease. Favorable safety profile together with MBC-11-dependent significant reduction in metabolic activity of bone lesions validate its further clinical development.”
The poster will be presented in the sessions listed below.
Abstract Number: 2589
Abstract Title: Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases.
Poster Board: 81
Presentation Date and Time: 6/5/2017, 8:00 AM-11:30 AM
Location: McCormick Place: Hall A
About Osteros Biomedica
Osteros Biomedica is Maxwell Biotech Venture Fund’s Portfolio Company. The Company’s main goal is to develop and commercialize innovative the drugs for the treatment of cancer induced bone disease. The company has the global rights for its first product MBC-11 which is being developed in collaboration with an American biotech company MBC Pharma.
About Maxwell Biotech Venture Fund
Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development.
SOURCE: Osteros Biomedica
Post Views: 164
